<DOC>
	<DOC>NCT00614939</DOC>
	<brief_summary>Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.</brief_summary>
	<brief_title>Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Diagnosed with type 2 diabetes Documented history of CrCl &lt;50 ml/min within the 3 months prior to enrollment HbA1c ≥7.0% and ≤11.0% Type 1 diabetes, history of diabetic ketoacidosis or hyposmolar nonketonic coma Previous or current treatment with any DPPIV inhibitor and/or GLP1 mimetic.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>DPP-4 inhibitors</keyword>
	<keyword>HbA1c</keyword>
	<keyword>incretins</keyword>
	<keyword>Renal Impairment</keyword>
</DOC>